CureVac NV - Asset Resilience Ratio
CureVac NV (5CV) has an Asset Resilience Ratio of 0.27% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2024)
This chart shows how CureVac NV's Asset Resilience Ratio has changed over time. Check CureVac NV (5CV) strategic asset index to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down CureVac NV's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see CureVac NV (5CV) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €3.12 Million | 0.27% |
| Total Liquid Assets | €3.12 Million | 0.27% |
Asset Resilience Insights
- Limited Liquidity: CureVac NV maintains only 0.27% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
CureVac NV Industry Peers by Asset Resilience Ratio
Compare CureVac NV's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Syndax Pharmaceuticals Inc
NASDAQ:SNDX |
Biotechnology | 46.79% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 63.47% |
|
Chengdu Kanghua Biological Products
SHE:300841 |
Biotechnology | 1.19% |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for CureVac NV (2018–2024)
The table below shows the annual Asset Resilience Ratio data for CureVac NV.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.45% | €3.62 Million ≈ $4.23 Million |
€802.83 Million ≈ $938.59 Million |
+0.11pp |
| 2023-12-31 | 0.34% | €2.66 Million ≈ $3.11 Million |
€788.25 Million ≈ $921.55 Million |
-0.18pp |
| 2022-12-31 | 0.52% | €4.49 Million ≈ $5.25 Million |
€860.47 Million ≈ $1.01 Billion |
+0.12pp |
| 2021-12-31 | 0.40% | €4.65 Million ≈ $5.43 Million |
€1.16 Billion ≈ $1.35 Billion |
+0.23pp |
| 2020-12-31 | 0.17% | €2.62 Million ≈ $3.06 Million |
€1.51 Billion ≈ $1.77 Billion |
-0.94pp |
| 2019-12-31 | 1.12% | €1.46 Million ≈ $1.70 Million |
€130.62 Million ≈ $152.71 Million |
-30.12pp |
| 2018-12-31 | 31.24% | €39.25 Million ≈ $45.89 Million |
€125.66 Million ≈ $146.91 Million |
-- |
About CureVac NV
As of December 18, 2025, CureVac N.V. was acquired by BioNTech SE. CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). The company's portfolio includes clinical and preclinical candidates for various disease indications in prophylactic vaccines, oncology, and molecular therapy. It also delivers optimized mRN… Read more